STI571:: Bcr-Abl kinase inhibition as the basis of therapy for CML

被引：0
|
作者：
Mauro, MJ [1 ]
Druker, BJ [1 ]
机构：
[1] Oregon Hlth Sci Univ, Portland, OR 97201 USA
来源：
LEUKEMIA | 2001年 / 15卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O23
引用
收藏
页码：488 / 488
页数：1
相关论文
共 50 条
  • [41] CML patients with resistance to STI-571 therapy could be monitored by real-time quantification of BCR-ABL transcripts.
    Amabile, M
    Martinelli, G
    Trabacchi, E
    Giannini, B
    Testoni, N
    Terragna, C
    Buonamici, S
    Ottaviani, E
    Soverini, S
    Bassi, S
    De Vivo, A
    Tura, S
    Alberti, D
    Baccarani, M
    BLOOD, 2002, 100 (11) : 320B - 320B
  • [42] Analysis of the structural basis of specificity of inhibition of the ABL kinase by STI571.
    Corbin, AS
    Toledo, LM
    Lydon, NB
    Buchdunger, E
    Kuriyan, J
    Druker, BJ
    BLOOD, 2000, 96 (11) : 470A - 470A
  • [43] Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)
    Thiele, J
    Kvasnicka, HM
    Varus, E
    Kriener, S
    Engels, K
    Staib, P
    Ollig, ES
    Griesshammer, M
    Waller, CF
    Pfeifer, H
    Schmitt-Gräff, A
    PATHOLOGE, 2004, 25 (06): : 428 - 435
  • [44] CML patients with complete karyotypic response to STI-571 (Glivec) therapy shows rapid reduction of bcr-abl transcripts.
    Giannini, B
    Martinelli, G
    Rosti, G
    Amabile, M
    Trabacchi, E
    Testoni, N
    Buonamici, S
    Ottaviani, E
    Soverini, S
    Bassi, S
    Pane, F
    Izzo, B
    Saglio, G
    Gottardi, E
    Alberti, D
    Baccarani, M
    BLOOD, 2002, 100 (11) : 785A - 786A
  • [45] Combined treatment of STI571 (Glivec) and curcumin synergistically suppresses the growth of K562 cells via inhibition of Bcr-Abl pathway
    Park, Juwon
    Bae, Eunkyung
    Yoon, Sung-Soo
    Kim, Byoung K.
    BLOOD, 2007, 110 (11) : 206B - 206B
  • [46] Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)
    Thiele J.
    Kvasnicka H.M.
    Varus E.
    Kriener S.
    Engels K.
    Staib P.
    Ollig E.S.
    Griesshammer M.
    Waller C.F.
    Pfeifer H.
    Schmitt-Gräff A.
    Der Pathologe, 2004, 25 (6): : 428 - 435
  • [47] Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571
    Koyama, N
    Koschmieder, S
    Tyagi, S
    Portero-Robles, I
    Chromic, J
    Myloch, S
    Nurnberger, H
    Rossmanith, T
    Hofmann, WK
    Hoelzer, D
    Ottmann, OG
    CLINICAL CANCER RESEARCH, 2006, 12 (07) : 2025 - 2031
  • [48] Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571
    Barthe, C
    Gharbi, MJ
    Lagarde, V
    Chollet, C
    Cony-Makhoul, P
    Reiffers, J
    Goldman, JM
    Melo, JV
    Mahon, FX
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (01) : 109 - 111
  • [49] The type of the bcr-abl transcript predicts the cytogenetic responses in chronic myelogenous leukemia patients treated with Glivec(STI571).
    Plouzeau, C
    Petinay, P
    Guilhot, J
    Brizard, F
    Bourmeyster, N
    Kitzis, A
    Brizard, A
    Bertaud, P
    Guilhot, F
    BLOOD, 2001, 98 (11) : 266B - 266B
  • [50] Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
    Agarwal, Anupriya
    Fleischman, Angela G.
    Petersen, Curtis L.
    MacKenzie, Ryan
    Luty, Samuel
    Loriaux, Marc
    Druker, Brian J.
    Woltjer, Randall L.
    Deininger, Michael W.
    BLOOD, 2012, 120 (13) : 2658 - 2668
12345